Next 10 |
home / stock / ncna / ncna articles
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, ...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer...
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis ...
NuCana plc (NASDAQ:NCNA) shares are trading lower by 15.2% to $0.26 during Thursday’s session after the company late Wednesday said it intend...
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expecte...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining over 100 points on Wednesday. The Dow traded up 0.28% to 39,113.63 w...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-exp...
NuCana Plc (NASDAQ:NCNA) shares are trading higher Wednesday after the company was granted a U.S. Patent for phosphoramidate derivatives for use in...
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 150 points on Wednesday. The Dow traded up 0.42% to 39,170.63 wh...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...